Abstract
Abstract
Background
Autosomal dominant polycystic kidney disease (ADPKD) is one of the most prevalent monogenic human diseases. It is mostly caused by pathogenic variants in PKD1 or PKD2 genes that encode interacting transmembrane proteins polycystin-1 (PC1) and polycystin-2 (PC2). Among many pathogenic processes described in ADPKD, those associated with cAMP signaling, inflammation, and metabolic reprogramming appear to regulate the disease manifestations. Tolvaptan, a vasopressin receptor-2 antagonist that regulates cAMP pathway, is the only FDA-approved ADPKD therapeutic. Tolvaptan reduces renal cyst growth and kidney function loss, but it is not tolerated by many patients and is associated with idiosyncratic liver toxicity. Therefore, additional therapeutic options for ADPKD treatment are needed.
Methods
As drug repurposing of FDA-approved drug candidates can significantly decrease the time and cost associated with traditional drug discovery, we used the computational approach signature reversion to detect inversely related drug response gene expression signatures from the Library of Integrated Network-Based Cellular Signatures (LINCS) database and identified compounds predicted to reverse disease-associated transcriptomic signatures in three publicly available Pkd2 kidney transcriptomic data sets of mouse ADPKD models. We focused on a pre-cystic model for signature reversion, as it was less impacted by confounding secondary disease mechanisms in ADPKD, and then compared the resulting candidates’ target differential expression in the two cystic mouse models. We further prioritized these drug candidates based on their known mechanism of action, FDA status, targets, and by functional enrichment analysis.
Results
With this in-silico approach, we prioritized 29 unique drug targets differentially expressed in Pkd2 ADPKD cystic models and 16 prioritized drug repurposing candidates that target them, including bromocriptine and mirtazapine, which can be further tested in-vitro and in-vivo.
Conclusion
Collectively, these results indicate drug targets and repurposing candidates that may effectively treat pre-cystic as well as cystic ADPKD.
Graphical Abstract
Funder
School of Medicine, University of Alabama at Birmingham
National Human Genome Research Institute
National Institute of Diabetes and Digestive and Kidney Diseases
Institutional Research and Academic Career Development Award
PKD Research Resource Consortium
Office of Research and Development, Medical Research Service
Detraz Endowed Research Fund in Polycystic Kidney Disease
Office of the Director
Publisher
Springer Science and Business Media LLC
Subject
Genetics (clinical),Genetics,Molecular Biology,Molecular Medicine
Reference99 articles.
1. Amiloride/hydrochlorothiazide black box warnings. Retrieved November 10, 2022, from https://online.epocrates.com/drugs/13211/amiloride-hydrochlorothiazide/Black-Box-Warnings. 2023
2. Asawa RR, Danchik C, Zahkarov A, Chen Y, Voss T, Jadhav A, Wallace DP, Trott JF, Weiss RH, Simeonov A, Martinez NJ. A high-throughput screening platform for polycystic kidney disease (PKD) drug repurposing utilizing murine and human ADPKD cells. Sci Rep. 2020;10(1):4203. https://doi.org/10.1038/s41598-020-61082-3.
3. Bellos I. Safety profile of tolvaptan in the treatment of autosomal dominant polycystic kidney disease. Ther Clin Risk Manag. 2021;17:649–56. https://doi.org/10.2147/TCRM.S286952.
4. Bromocriptine Adverse Reactions. Retrieved November 10, 2022, from https://online.epocrates.com/drugs/405/bromocriptine/Adverse-Reactions. 2023
5. Cadnapaphornchai MA, George DM, McFann K, Wang W, Gitomer B, Strain JD, Schrier RW. Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol CJASN. 2014;9(5):889–96. https://doi.org/10.2215/CJN.08350813.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献